α-Synuclein in traumatic and vascular diseases of the central nervous system

Hong Zeng¹, Nan Liu¹, Xiao-Xie Liu¹, Yan-Yan Yang¹, Mou-Wang Zhou¹

¹Department of Rehabilitation Medicine, Peking University Third Hospital, Beijing 100191, China

Correspondence to: Mou-Wang Zhou, Yan-Yan Yang; email: zhoumouwang@163.com, https://orcid.org/0000-0003-1553-0613; yyxkaixin@163.com, https://orcid.org/0000-0003-3240-9030

Keywords: α-Synuclein, spinal cord injury, brain injury, ischemic stroke, posttranslational modification

Received: January 30, 2020 Accepted: June 29, 2020 Published: November 7, 2020

ABSTRACT

α-Synuclein (α-Syn) is a small, soluble, disordered protein that is widely expressed in the nervous system. Although its physiological functions are not yet fully understood, it is mainly involved in synaptic vesicle transport, neurotransmitter synthesis and release, cell membrane homeostasis, lipid synthesis, mitochondrial and lysosomal activities, and heavy metal removal. The complex and inconsistent pathological manifestations of α-Syn are attributed to its structural instability, mutational complexity, misfolding, and diverse posttranslational modifications. These effects trigger mitochondrial dysfunction, oxidative stress, and neuroinflammatory responses, resulting in neuronal death and neurodegeneration. Several recent studies have discovered the pathogenic roles of α-Syn in traumatic and vascular central nervous system diseases, such as traumatic spinal cord injury, brain injury, and stroke, and in aggravating the processes of neurodegeneration. This review aims to highlight the structural and pathophysiological changes in α-Syn and its mechanism of action in traumatic and vascular diseases of the central nervous system.

Structure of α-Synuclein

α-Syn is composed of 140 amino acids. Snca encodes α-Syn, and wild-type (WT) α-Syn is an inherently disordered protein (IDP). The gene encoding the protein is located on human chromosome 4 and occupies a region of approximately 114 kb in the genome. α-Syn accounts for 1% of the total protein content of neurons and has a predominantly presynaptic localization. It is widely distributed within neurons and is found in the cytoplasm, nucleus, mitochondria, and mitochondria-associated membranes. In the cytoplasm, one-third of the protein binds to the synaptic membrane [1–3]. α-Syn has no persistent structure under physiological conditions and is mainly monolithic and inherently disordered.

Under physiological conditions, α-Syn displays a disordered structure in vitro. Its sequence is usually divided into the following three main regions (Figure 1):

- The N-terminal amphipathic domain (residues 1–60): The amphiphilic N-terminal domain (NTD) is composed of six imperfect repeats (KTKEGV) with which the protein interacts with lipids.

- The nonamyloid β component (NAC) region (residues 61-95): This is a central hydrophobic region with oligomeric properties that participates in α-Syn protein aggregation and appears to be essential for α-Syn fibril formation. It integrates with the highly acidic C-terminal domain (CTD). Since these interactions involve electrostatic properties, the ionic strength or pH of the solution can strongly increase the aggregation of α-Syn [4].

- The CTD (residues 96-140): This is a highly acidic and proline-rich region with no obvious structural tendency. The negative charge in the acidic portion of the CTD, confers chaperone-like properties and can inhibit the oligomerization process, which is essential for preventing rapid α-Syn fibrillation [5].
Natural α-Syn is usually an IDP or unstructured monomer, and the disordered monomer form is the main state of α-Syn in aqueous solution. The α-Syn tetramer is another form with a stable helix structure that coexists with the monomer in the cell [6]. The use of denaturing detergents and cell lysis methods may destabilize the tetramers, thereby forming monomers. Tetramer can maintain α-Syn steady state and resist aggregation [7]. Therefore, α-Syn naturally exists as a helical tetramer, and it is in a dynamic equilibrium state with disordered monomers, which is the overall dominant state. Missense mutations in the α-Syn gene reduce the ratio of the tetramer to the monomer, which promotes the transition to a disease state.

The Physiological Function of α-Syn

In nondisease states, the function of α-Syn is still poorly understood, although increasing evidence suggests that the protein mediates the transport of vesicle axons, regulates neurotransmitter release, and mediates the interaction and assembly of synaptic vesicles. It also undergoes strong binding to negatively charged vesicles in vitro and has the function of inhibiting membrane fusion [8]. The physiological effects of neurons rich in α-Syn expression include maintenance of mitochondrial morphology, regulation of transport, and clearance of substances. Recent reports indicate that α-Syn may benefit to improve neuronal microtubule dynamics and lymphocyte development [9–10]. In short, its biological function is inseparable from the biological significance of cell membrane homeostasis and synaptic regulation. Therefore, vesicles composed of mixed lipids, which mimic lipids in neuronal cells, should be studied to discover the true biological significance of α-Syn in vivo and in vitro.

α-Syn participates in synaptic vesicle transport and neurotransmitter synthesis and release

In rodents, α-Syn expression is detected shortly after birth, continues to increase until one month of age, and

![Figure 1. Structural characteristics of α-Syn monomers and fibril aggregates.](https://www.rcsb.org/)

(A) α-Syn is composed of three different regions: a positively charged amphiphilic N-terminus (residues 1-60), a hydrophobic nonamyloid (NAC) region (residues 61-95), and a negatively charged CTD (residues 96-140); they may have different functions. (B) The secondary structure of α-Syn. (C) The structure of the amino acid residues of α-Syn. (D) The fibril structure (secondary structure) of α-Syn. (E) The fibril structure (amino acid residues) of α-Syn. All the structure diagrams are from the PDB database ([https://www.rcsb.org/](https://www.rcsb.org/)), and the corresponding colors are marked.
then reaches a stable level that persists into adulthood. Similarly, in cultured rat neurons, synaptic development preceded the expression of α-Syn and translocation to the axonal end [11]. α-Syn is an intracellular protein, and under physiological conditions, the level of α-Syn in the central nervous system (CNS) is quite high. However, it has been suggested that a large proportion of α-Syn may be extracellular and may be secreted and transmitted between neuronal cells [12]. α-Syn is present in biological fluids, such as cerebrospinal fluid (CSF) and plasma, in patients and normal subjects, which is also evidence of α-Syn release. α-Syn is also found in peripheral neurons, hematopoietic cells in the bone marrow, and circulating blood cells, including red blood cells (RBCs), platelets, and lymphocytes; this distribution depends on α-Syn transport between cells, which occurs via exosomes and other extracellular vesicles (EVs) [13].

α-Syn participates in the dynamics of synaptic vesicle transport, promotes the interaction between synaptic vesicles, and improves their assembly, providing support for the functions of exocytosis and endocytosis, in which stability of the membrane is a key step [14]. Evidence suggests that α-Syn is involved in synaptic vesicle transport, i.e., vesicle docking, recovery and/or reaggregation. Physiologically, α-Syn acts as a soluble NSF attachment protein receptor (SNARE) chaperone, promoting the assembly of the SNARE complex to release neurotransmitters, with involvement in dopamine (DA) synthesis, transport and recovery. α-Syn maintains the stability of neurotransmitters by regulating synaptic vesicle fusion, aggregation and transport between the storage and releasable pools, as well as the interaction with neurotransmitter membrane transporters. In addition, supplementing the activity of cysteine choline protein α (CSPα) promotes synaptic integrity [15]. The selective regulation of glutamate neurotransmission alters the level of extracellular α-Syn. It is possible that the mechanism of α-Syn activity-dependent release participates in specific neural networks, maintaining precise control of the neurotransmitter cycle (Figure 2).

**α-Syn is involved in cell membrane homeostasis**

α-Syn is a soluble protein that transiently fused to the membrane. Studies have shown that the balance between order and disorder in the α-Syn protein system is essential for the regulation of membrane affinity, which can induce synaptic vesicle aggregation and self-assembly into amyloid fibrils on the surface of biofilms. Of course, the more complex membrane components are not easily damaged by oligomers. At the structural level, the separation between the helical binding conformation and the disordered conformation, especially around the NAC region, seem to affect the key properties of α-Syn, such as the promotion of membrane-binding affinity or synaptic vesicles [16]. NTD acetylation to form the NTD helix can stabilize the interaction of the lipid membrane with α-Syn micelles and increase the affinity of the NTD for physiological membranes [17]. The ability of proteins to combine with lipids to promote the α-helical conformation of the NTD segment has been fully demonstrated. This prevents fibrils from forming and stabilizing physiological polymers, which together with monomers can improve the assembly of SNARE complexes and the circulation of synaptic vesicles [1, 19]. At the molecular level, the ability of α-Syn to form pores in biofilms or to interact with specific proteins in organelles and the cytoplasm may be the factor that determines the toxicity of this protein [18]. In summary, there is increasing evidence that the balance between the ordered and disordered conformations of α-Syn on the surface of biofilms is critical for membrane stability.

**α-Syn participates in mitochondrial activities**

Neurons, Ranyier somatic cells, synapses, and nodes all have high energy requirements. The maintenance of mitochondrial dynamics involves multiple processes that ensure that these high energy requirements are met, namely, fusion, fission, transport, and engulfment [20], whose functions include mitigating pretouch Ca2+ levels, maintaining the membrane potential, and transport along axons and nerves. The absorption and recycling of transmitters provides energy [21]. Each of these processes is interconnected through complex relationships that maintain a functional mitochondrial network throughout the neuron life cycle. Monomeric α-Syn can increase ATP synthase efficiency and mitochondrial function [22]. At nanomolar concentrations, α-Syn reversibly blocks voltage-dependent anion channels (VDACs), which are the main channels in the outer mitochondrial membrane and control the passage of most metabolites into and out of mitochondria, protecting cells from oxidative stress [23].

**Other functions**

The expression of WT α-Syn in primary brain cells also protects the cells from neurotoxicity caused by manganese [24]. Hsiao et al. reported a new role of α-Syn, highlighting its importance in neuronal cholesterol regulation, and identified novel therapeutic targets for controlling cellular cholesterol levels [25]. Eichmann et al. observed that α-Syn can form high-density lipoprotein-like (HDL-like) particles, and all human Syn proteins can form stable and homogeneous HDL-like particles with different morphologies [26].
Pathological Characteristics and Pathogenic Mechanism of Aggregated α-Syn

The most complicated and diverse aspect of aggregated α-Syn is its pathological manifestations. Due to its structural instability and the complexity of its mutations, there is neither a precise pathological mechanism nor a clear targeted drug for this protein. Toxic α-Syn forms can negatively affect various key cellular processes, including mitochondrial function, endoplasmic reticulum (ER) stress, and protein folding, leading to cell dysfunction and death, protein degradation, and abnormal axonal transport and presynaptic function [18]. The pathogenic mechanism

Figure 2. Schematic of the physiological role of α-Syn in synaptic transmission. The figure shows that α-Syn (monomeric and tetrameric forms) is involved in neurovesicle transport during the intricate transmission of neurotransmitters in synapses, dendrites and axons; this transport includes neurotransmitter vesicle storage, aggregation, assembly and release, as well as recovery and inhibition of neurotransmitters and other circulatory processes. α-Syn is also involved in the maintenance of cell membrane homeostasis and the normal functioning of mitochondria and lysosomes.
and pathological characteristics of α-Syn have been explored from the following perspectives.

**Characteristics of α-Syn aggregation**

In disease states, α-Syn has an increased tendency to self-assemble and can form more than one type of small assembly (for example, dimers, trimers, tetramers, and larger oligomers); these assemblies have a fibril structure with a β-sheet structure, up to the size of inclusion bodies (i.e., Lewy bodies, LBs) [27]. Dimerization is the first step of α-Syn aggregation and accelerates α-Syn aggregation at acidic pH due to electrostatic effects [28]. For example, aggregates proliferate much faster in certain intracellular locations (including the ER and lysosomes) at a moderate acidic pH (6) than at a normal physiological pH [29]. In addition, point mutations promote dimerization and indicate that the structural heterogeneity of α-Syn dimers may lead to different aggregation pathways [30]. The dimerization of α-Syn accelerates the formation of fibrils. The dimer's β-hairpin region is adjacent to the nonamyloid β component (NAC) of α-Syn. Since the formation of the β-hairpin can accelerate the aggregation of α-Syn, small molecules that can bind to these regions and inhibit the process of β-hairpin formation may effectively inhibit α-Syn aggregation [31]. Furthermore, α-Syn oligomers with the same mass concentration are more effective than monomers or fibrils in clearing lipid vesicles. The conversion mechanism from soluble α-Syn monomers to disease-related oligomers, especially dimers, has become a hot topic of recent research.

PTMs of α-Syn, including phosphorylation, nitration, ubiquitination, glycosylation, and CTD truncation, are the main cause of its oligomerization [32], and there are multiple combinations of simultaneous modifications.

**Phosphorylation**

A gradient of phosphorylated α-Syn accumulates in synapses (presynaptic>presynaptic+postsynaptic>postsynaptic), and phosphorylated α-Syn was found at presynaptic ends in dementia patients with LBs, mainly manifesting as small phosphorylated α-Syn aggregates, which are related to changes in synaptic morphology. Overall, pathologically phosphorylated α-Syn may disrupt the structure and function of synapses in patients with LB dementia [33]. In the brains of healthy individuals, only a small portion (4%) of the total α-Syn is phosphorylated at residue Serine-129 (Ser-129). In contrast, in Parkinson's disease (PD) brains containing LBs, Ser-129 phosphorylation is the most common (approximately 90%) form of PTM for α-Syn [34]. In conclusion, Ser-129 phosphorylation of α-Syn can promote the accumulation of oligomeric α-Syn *in vitro* and can accelerate the formation of α-Syn inclusions.

**Nitrosation**

Research suggests that Tyr-125 may promote the dimerization of α-Syn under nitrosation stress, leading to its subsequent oligomerization [35]. Oxidation and nitration of tyrosine residues in preassembled α-Syn fibers can stabilize these fibers and enhance the formation of sodium lauryl sulfate (SDS)-insoluble, thermally stable polymer aggregates, indicating that oxidative stress and nitrosyl stress are involved in its pathogenesis [36]. In addition, the intermolecular interaction between NTD and CTD of α-Syn induces α-Syn oligomerization mediated by nitrification.

**Ubiquitination**

Several proteolytic systems are involved in dysfunctional degradation pathways and α-Syn aggregation, including the ubiquitin proteasome system (UPS) and the autophagy lysosomal pathway (ALP) during α-Syn degradation [37]. α-Syn aggregates colocalize with ubiquitin in an immunoreactive manner in neurons. Although this nitrosation stress is partly the result of the inflammatory changes produced by α-Syn, there is also evidence that NO causes abnormal protein accumulation by disrupting the UPS. The UPS is mainly responsible for the short-term degradation of soluble proteins, while the ALP can degrade long-standing macromolecules and cytoplasmic components, leading to functional organelle disorders. The failure of these functionally interconnected proteolytic systems may be accompanied by the accumulation of aggregated α-Syn, which will eventually interfere with normal cellular function and promote the pathogenesis of PD [38].

**Glycosylation**

Glycosylation enhances α-Syn-related neurodegeneration in synucleinopathy. Glycosylation increases the oligomerization of α-Syn and interferes with the NTD of the protein, thereby reducing the capacity of α-Syn to bind to the lipid membrane. Saccharification is an inevitable age-related PTM that enhances α-Syn toxicity. Glycosylation reduces membrane binding, hinders the clearance of α-Syn, and promotes the accumulation of toxic oligomers, thereby impairing neuronal synaptic transmission [39]. Glucose is easily metabolized to produce reducing sugars, which covalently react with proteins to produce advanced glycosylation end products (AGEs), which are always responsible for protein function [40]. With age, brain defenses against glycosylation (such as glutathione, reduced glutathione and GLO1, and the glyoxalase system (GLO1)) decrease, as in the
substantia nigra (SN) in PD [41]. Methylglyoxal levels increase α-Syn glycosylation and increase with age and PD [42]. In addition, glycosylation has long been known to enhance neurodegeneration in a Huntington disease model, further suggesting a link between hyperglycemia and neurodegeneration [43]. Determining the molecular mechanism by which glycosylation alters protein homeostasis and contributes to synucleosis can lead to an important breakthrough, linking aging to neurodegeneration and supporting the discovery new therapeutic targets for intervention in synucleosis. In addition, glycosylated α-Syn can impair the long-term enhancement of the hippocampus [42]. Overall, disturbances in the stable components of these glycosylated proteins can lead to the accumulation, aggregation, and cytotoxicity of α-Syn.

**CTD truncation**

The conformational changes in the CTD of α-Syn in cells may be involved in the initial steps by which exogenous α-Syn aggregates form fibrils [44]. The truncated α-Syn form of CTD strongly induced the formation of LB. Intracellular repair after oxidative damage fails to target the CTD modification site of α-Syn [45]. Specific physiological CTD-truncated forms of α-Syn have significant aggregation properties, including the capacity to increase the virus-like aggregation and inoculation activities of α-Syn fibrils. In addition, CTD truncation exacerbates aggregation and α-cytotoxic synuclein, forming a vicious cycle in PD [46]. CTD-truncated fibrils show superior spread in stimulating α-Syn aggregation, and CTD α-Syn truncation in LBs is associated with cysteine protease activity, promotes amyloid formation and contributes to the pathogenesis of PD [47].

**Aggregated α-Syn and mitochondrial dysfunction**

The α-Syn protein can directly form plasma membrane channels or change its activity, thereby changing the membrane's permeability to ions; this protein is also associated with mitochondrial abnormalities leading to mitochondrial dysfunction (i.e., mitochondrial depolarization, Ca^{2+} metabolic imbalance, and cytochrome C release), interference with autophagy regulation, and alteration of calcium homeostasis or mitochondrial fragmentation [48]. The interaction of α-Syn with spectrin causes pathological changes in the actin cytoskeleton and induces mitochondrial dysfunction and downstream neurotoxicity [49]. The pathogenic characteristics of α-Syn misfolding are also time-dependent pathological cascades of toxic reactions that begin with mitochondrial oxidative stress, lead to the accumulation of oxidized DA, and ultimately cause reduced glucocerebrosidase (GCase) activity, lysosomal dysfunction and α-Syn accumulation.

**Aggregated α-Syn and lysosomal dysfunction**

*In vivo*, lysosomes engulf misfolded α-Syn aggregates, but incomplete lysosomal clearance mechanisms can also promote the accumulation of soluble α-Syn oligomers, which may be the key to disease progression [50]. Incorrect presynaptic peripheral α-Syn aggregation leads to lysosomal dysfunction, and this restoration of presynaptic function prevents neurodegeneration caused by lysosomal storage disease [51]. In sporadic PD, the probability of heterozygous mutations in the lysosomal hydrolase GBA1 is approximately 7%. GBA1 mutations that cause a moderate reduction in GCase by 30-50% can promote the development of PD, but the mechanism is not clear. In short, the presence of normal lysosomes and α-Syn are complementary factors that influence each other.

**Aggregated α-Syn, oxidative stress and free radical damage**

Compared with surrounding organs, the brain is extremely susceptible to oxidative stress due to its extremely high polyunsaturated fat content and relatively low antioxidant activity [52]. Toxic α-Syn oligomers can affect cells in a variety of ways, including membrane destruction, mitochondrial depolarization, cytoskeletal changes, impaired protein clearance pathways, enhanced oxidative stress, and free radical damage. Much evidence shows that there is a two-way relationship between the oligomeric nature of α-Syn and the generation of reactive oxygen species (ROS) [53]. Lipid peroxidation promotes intracellular accumulation and then squeezes out toxic α-Syn as the “seed” [54]. This “seed” is then internalized by neighboring neurons, spreading the neurodegeneration process. The oxidative stress reaction destroys the ability to scavenge free radicals. Excessive free radicals can trigger the pathological production of misfolded proteins, lead to abnormal mitochondrial function, and stimulate neuronal cell apoptosis pathways [55]. The peroxidase activity of cytochrome C contributes to the formation of free radicals and α-Syn oligomerization, and α-Syn increases neuronal death by colocalizing with cytochrome C [56].

**Aggregated α-Syn and neuroinflammation**

In PD and related diseases, it is important to understand the exact mechanisms of glial regulation [57], which can trigger changes in the CNS immune microenvironment, leading to outcomes such as proinflammatory responses. We propose a mechanism
in which α-Syn secreted from neurons acts as a trigger that causes changes in glial cells. Studies have shown that α-Syn fibrils begin to recruit major histocompatibility complex class II (MHC II)-expressing cells in the rat brain before neurodegeneration begins; these cells consist of both resident microglia and peripheral cells, including monocytes, macrophages and lymphocytes [58]. Microglia serve as innate immune cells in the CNS. On the one hand, microglial activation is necessary to clear debris from apoptotic DA neurons. On the other hand, microglial overactivation leads to free radical damage and increases the production of cytokines and chemokines. Astrocytes have multiple functions in the CNS, from brain development to synapse formation and from blood flow barrier control to myelin sheath formation. Astrocytes have also been confirmed in other neurodegenerative diseases for which protein accumulation is a key pathological marker [59]. After neurons transfer α-Syn to astrocytes, astrocytes display a proinflammatory response, producing a variety of proinflammatory cytokines and chemokines. From these findings, the importance of astrocytes in the inflammatory process that progresses during synucleosis has been demonstrated.

**The Mechanism of α-Syn in Traumatic CNS Diseases**

**Traumatic spinal cord injury**

**Overview of spinal cord injury**

Spinal cord injury (SCI) is a serious CNS trauma of the spinal cord that involves various causes of organizational structure and functional impairment and results in varying degrees of damage to sensory and motor functions, causing SCI-related autonomic dysfunction (AD) [60–61]. The disease can lead to permanent disability, with its attendant sudden autonomic function disorders such as orthostatic hypotension, autonomic reflexes, sympathetic activity surge failure and bladder, rectum, and sexual dysfunction [62]. SCI causes substantial pain to patients but is also a heavy burden for society and countries. In recent years, the incidence of SCI has shown annual increases. According to the literature, the annual incidence of SCI in Asian countries and regions is approximately 19.5-56.1 cases per million people, with 11,000 new cases of SCI in the United States per year [63]. For the first time in years, the burden of SCI was estimated at more than 900 million cases in 2016 [64]. From the perspective of the pathophysiology of SCI, the primary injury is usually attributed to local injury, which directly causes tissue defects, edema and neuronal death at the injury site; however, the more destructive lesions are secondary injuries. Many studies, including our earlier studies, have found that tissue lesions after SCI are time-dependent and spatially progressive. The damage increases with time, and more distant parts of the spinal cord are involved [65]. Typically, a series of biochemical cascade events, including activation, inflammatory mediators, oxidative stress and free radical damage, abnormal protein aggregation (including α-Syn) and glial cell activity, result in delayed neuronal death [62, 64, 66]. A secondary SCI injury can develop several months after the early stages of SCI development and is the current focus of a series of modern medical interventions.

**α-Syn-Ser-129 phosphorylation and SCI**

It is unclear what causes the transformation between the physiological function and pathological aggregation tendencies of α-Syn, and this active conformational change also suggests that the balance between normal and abnormal behavior of the protein is very delicate. α-Syn-Ser-129 phosphorylation and dephosphorylation, the main PTM modes, are regulated by protein kinases and protein phosphatases, respectively. It is unclear which kinases phosphorylate Ser-129 on α-Syn in cases of disease. Polo-like kinase 2 (PLK2) is an important serine/threonine kinase that phosphorylates α-Syn at Ser-129 [67]. Neuropathological analysis of the brains of elderly nonhuman primates showed that increased expression of PLK2 was associated with increased levels of phosphorylated Ser-129-α-Syn. In addition, PLK2 was colocalized with phosphorylated Ser-129-α-Syn [68]. This finding supports the important role of PLK kinases in α-Syn phosphorylation at Ser-129 in the brain and suggests that PLK2 is responsible for this activity under physiological conditions [67]. Overexpression of PLK2 and PLK3 in DA neurons induces endogenous Ser-129 phosphorylation of α-Syn; however, its survival is not impaired, and the effect of functional phosphorylation on the interaction of α-Syn with specific protein chaperones may be significant and highly site-specific [68]. Sato et al. overexpressed G protein-coupled receptor kinase 6 (GRK-6), which increased the content of Ser-129-phosphorylated α-Syn in DA neurons and caused strong neurodegeneration and α-Syn pathological inclusions [69]. Protein phosphatase 2 (PP2A) is a ubiquitous cytoplasmic serine/threonine phosphatase that accounts for more than 50% of the serine/threonine phosphatase activity in the brain. PP2A is important for α-Syn dephosphorylation at Ser-129. Insoluble α-Syn can reduce the activity of PP2A, and overexpression of PP2A can prevent neuropathological changes in mice caused by overexpression of α-Syn. Metformin reduces Ser-129-phosphorylated α-Syn levels through mTOR-
Our research on SCI found that α-Syn is an important promoter of neuroinflammation. Microglial cells phagocytose α-Syn accumulated in the environment and have the capacity to target light chain 3B (LC3B)+ autophagosomes for degradation [80]. In addition, microglial Fc-γ receptors (FcγR) take up extracellular accumulated α-Syn, triggering a downstream NF-κB-dependent signaling cascade (including chemokine production) [81]. Interestingly, FcγR-/- mice were protected from neuroinflammation and neurodegeneration after AAV-mediated α-Syn overexpression, suggesting that phagocytosed aggregated α-Syn enters microglia, which is important for inducing an immune response that causes neurodegeneration [81]. Fu H et al. suggested that complement components, especially C3 and CR3, may be related to microglial uptake of α-Syn [82].

In SCI secondary injury, silencing α-Syn can reduce the activation of microglia/astroglia, reduce the expression of iNOS, and reduce microglial toxicity via phenotypic transformation from the M1 phenotype to the protective M2 phenotype; these effects are accompanied by a significant increase in Arg-1 and IL-10 expression and regulation of neuroinflammation in the spinal cord. α-Syn-silenced rats also showed reduced IL-1β, TNF-α, and IL-2 expression in serum from peripheral blood, which significantly increased the expression of the anti-inflammatory cytokine IL-10. In addition, we also tested whether downregulating α-Syn can reduce the expression of matrix metalloproteinase-9, which may improve the function of the blood-spinal cord barrier, which is the key barrier for maintaining the stability of central and peripheral immunity [72]. Overexpression of neuronal α-Syn results in increased expression of type 1 angiotensin receptors and increased NADPH oxidase activity, as well as significant increases in the number of OX-6-positive microglia and iNOS, TNF-α, IL-1β, and IL-6 expression [83]. In addition, markers of immunomodulatory M2 microglial phenotypes, such as Arg1, have been observed to decrease significantly; however, this phenomenon was observed concomitantly with concurrent use of the angiotensin type 1 blockers candesartan and telmisartan, which are inhibited by treatment [16]. Mesenchymal stem cells (MSCs) enhance α-Syn clearance via M2 microglial polarization [84]. When the immunodegradation and repair processes of M2 microglia are inhibited, M1 microglia dominate the damage site at the end of the disease; it is unknown whether these two phenotypes are compatible or contradictory, but α-Syn changes the microglial phenotype to complicate the disease. We comprehensively analyzed the effects of α-Syn knockdown on transcript levels in SCI through transcriptomics technology and found that enhancement of the cholinergic pathway may be an important way to

---

### α-Syn and SCI neuroinflammation

PTMs of α-Syn can cause the activation of microglia or monocytes and produce corresponding proinflammatory cytokines. α-Syn acts on Toll-like receptor 2 (TLR2) on microglia. TLR2 transmits the α-Syn signal that triggers the cascade, but there is also the possibility that other secondary receptor molecules participate in the internalization and clearance processes. Qiao et al. demonstrated with in vivo and in vitro experiments that neurons subjected to ischemia/reperfusion in the injured spinal cord have increased levels of α-Syn expression and release and cause microglial activation through TLR2 [73]. In WT oligo-α-Syn-pretreated rat primary microglia, TLR-2 was upregulated, and it was interesting that TLR-3 and 7 were downregulated; TLR-2 knockout (KO) inhibited the inflammatory factors TNF-α and IL-1β [74]. Furthermore, only secreted forms of α-synuclein oligomers were identified as capable of activating TLR2, while neuronal cytoplasmic α-synuclein did not activate TLR2. In addition, it has been speculated that TLR4 is also involved in α-Syn-induced microglial and astrocyte activation [75]. Furthermore, Qiao et al. demonstrated the role of α-Syn in microglial migration by isolating primary microglial cells from Sprague Dawley rats and exogenously exposing them to three different doses of SNCA oligomers [76]. Another study by Qiao et al. demonstrated that α-Syn induces microglial migration through pyruvate kinase M2-dependent glycolysis [77]. Based on qRT-PCR and western blot data, the authors also found that SNCA can increase the mRNA and protein levels of hypoxia-inducible factor-1α (HIF-1α) in microglia in a dose-dependent manner [76]. In addition, HIF-1α has been shown to be involved in microglial chemotaxis and the release of proinflammatory cytokines [77, 78]. Nitrogen-aggregated α-Syn activates primary microglia and increases the production of TNF-α, interleukin-1β (IL-1β), monocyte chemotactic protein-1 (MCP-1) and interferon-γ (IFN-γ) [79].
reduce neuroinflammation. Promoting neurogenesis by reducing α-Syn at the site of SCI injury may be due to the upregulation of muscarinic cholinergic receptor subtype 2 (Chrm2) and nicotinic cholinergic receptor β2 (Chrnβ2) on the cholinergic pathway [65].

**Propagation of α-Syn and SCI**

α-Syn folding and assembly can produce species with different pathological effects: easy-to-extend fibrillar-like oligomers with parallel β-sheet arrangements can be used for disease and key pathogen transmission, and oligomers with antiparallel β-sheet arrangements can accumulate in cells [85]. From a micro perspective, the spread of α-Syn from cell to cell requires that α-Syn be released into the extracellular space and absorbed by recipient cells. In addition, intrinsic α-Syn requires access to the cytoplasm and/or target organelles of recipient cells. The virus-like hypothesis of α-Syn pathology proposes a method of transmitting misfolded α-Syn from one neuron to another. This hypothesis assumes that misfolded α-Syn effectively aggregates. When released and absorbed by adjacent cells, this pathological α-Syn forms a "seed", which will further misfold and aggregate. This assembly resembles a "prion", with self-replicating and self-transmitting capacities and this novel "prion" behavior may further lead to synaptic failure in synucleinopathy [86].

Transplantation of pathological α-Syn in the brain can cause rapid progressive neurodegenerative synucleinopathy in mice [87]. α-Syn spreads disease through self-modeling mechanisms similar to those of viral diseases, such as Creutzfeldt-Jakob disease [27].

From a macro perspective, the pathology of α-Syn diffuses into the brain and can deteriorate the surrounding autonomic and somatic nervous systems [87]. A major pathway of disease progression may originate in the enteric nervous system, reach the dorsal motor nucleus of the vagus nerve of the lower brainstem in a retrograde manner and travel along the brainstem to the midbrain, forebrain and cerebral cortex. The spinal cord center may be involved through the descending projection of the lower brainstem nucleus and the sympathetic projection that connects the enteric nervous system to the peripheral ganglia and preganglionic nucleus of the spinal ganglia [88]. Many synucleinopathies are accompanied by AD. A large number of α-Syn aggregates can be detected in the intestinal autonomic nerves of SCI patients, further illustrating that the transmission of α-Syn may occur in weak autonomic nerves with myelinization. Interestingly, research has found that nornicotine, a nicotine metabolite involved in saccharification, chemically modifies amyloid to prevent aggregation [89]. In summary, the development of experimental cells and animal models can help explain the mechanism by which aberrant α-Syn aggregates and the mechanism by which axonal connectivity spreads, which has facilitated the initiation of improved disease treatment strategies for potential synucleinopathy. Recently, accumulated evidence has shown that there is a close relationship between the differential expression profile of α-Syn and the selective vulnerability of certain neuronal populations.

PD and other neurodegenerative diseases associated with changes in α-Syn often cause AD, and in most cases, this synapse protein is expressed in large amounts in peripheral autonomic neurons [90]. SCI is often accompanied by AD, and its pathogenesis is unclear, but it may be related to the selective involvement of α-Syn in autonomic neurons. Perivascular nerve fibers containing α-Syn were detected in the aortas of mice, while aortic endothelial cells and muscle fibers containing the protein were not detected. α-Syn is present in the sympathetic fibers supplying the rat aorta and provides evidence that changes in the α-Syn levels in the perivascular fibers contribute to regulating vascular function [91].

**New treatment direction for SCI: target α-Syn**

α-Syn has many important influences on the physiological and pathological processes of SCI due to its unique structure and its important presynaptic structure in the CNS. The overexpression or aggregation of α-Syn increase neuroinflammation after SCI. Sakurai et al. observed biomarkers in rabbits with persistent SCI and noted that motor neurons (neurons that were eventually found to be dead) were stimulated to increase α-Syn levels 8 hours after stimulation [78]. Feng et al. showed that SNCA was also downregulated to promote the expression of ciliary neurotrophic factor (CNTF), inhibit neuronal apoptosis, and promote neural regeneration [92]. Many studies have targeted the treatment of neuroinflammation induced by α-Syn. For example, methyl jasmonate, an effective antioxidant and anti-inflammatory compound, delays PD, possibly by inhibiting oxidative stress, releasing proinflammatory cytokines, and downregulating the expression of NF-κB and α-Syn [93]. Apigenin protects rat models of PD from neurodegeneration and degeneration by inhibiting neuroinflammation and oxidative stress-mediated apoptosis [94]. Lipoprotein deficiency increases the aggregation and phosphorylation of α-Syn and neuroinflammation by reducing peroxisome proliferator-activated receptor γ (PPARγ), which causes age-related loss of dopaminergic neurons and impaired motor coordination [95]. Similarly, the (molecular chaperone) cluster protein and α2-macroglobulin bind directly to the exposed hydrophobic region on the surface of the α-Syn oligomer. The combination of these two molecular chaperones reduces the capacity of
the oligomer to permeate the lipid membrane and prevents oligomer-induced increases in ROS production in cultured neuronal cells [96]. Interestingly, motor neuron numbers were improved by vagus nerve stimulation [97]. In addition, knocking down α-Syn can improve neuronal survival in the cerebral cortex of SCI rats. More significantly, Jankovic et al. also studied the safety of an anti-Syn antibody (PRX002) in humans, which may prove beneficial for reducing the progression of neurodegenerative diseases that occur after acute SCI in humans [98].

In general, α-Syn is mainly involved in glial cell recruitment, activation and migration; phenotypic changes after SCI; neuroinflammation; increased expression of inflammatory mediators; changes in neurotransmitters, such as dopaminergic and cholinergic neurotransmitters; and changes in neuroprotective factors, such as CNTF. Targeting α-Syn may be of great significance in the diagnosis and treatment of SCI.

**Traumatic brain injury**

Traumatic brain injury (TBI) is one of the leading causes of death among young people in developed countries. In the United States, 1.7 million traumatic events occur each year, causing 50,000 deaths. The causes of TBI include traffic accidents, falls, gunshot wounds, sports, and combat-related incidents [99]. As with SCI, the initial injuries of TBI are caused by mechanical factors that damage neural tissue. From animal experiments to clinical studies, secondary lesions appear a few minutes after trauma and can develop for months or even years. Cell and molecular events lead to the secondary events of brain cell death and neurodegeneration, which are accompanied by a high risk of certain neurodegenerative diseases [100]. Cognitive impairment becomes a major sequela of TBI in rodent models or patients with secondary injury [101]. Another study showed histological evidence of chronic traumatic encephalopathy (CTE) in neurodegenerative diseases, with PD accounting for 16% of cases [102]. The biological mechanisms that connect brain trauma and neurodegenerative diseases require further study. Studies on the correlation between chronic TBI and other neurodegenerative diseases have shown that repetitive TBI promotes the accumulation of abnormal aggregate proteins, including TAR DNA-binding protein 43, amyloid beta protein and α-Syn. Increased α-Syn in the CSF was observed in patients with severe TBI (p = 0.0008). A large increase in α-Syn in the CSF may indicate widespread neurodegenerative changes and reflect secondary neuropathological events that occur after injury [103]. Similarly, in a study of the feasibility of α-Syn as an objective biomarker for the diagnosis and prognosis of mild TBI, it was believed that amyloid-β (Aβ) peptide, tau protein and α-Syn are involved in the downstream events of the TBI-induced idiopathic cascade [104]. In patients with severe TBI, it is often difficult to predict survival or long-term outcomes, especially in the first few days after injury, but the α-Syn levels in patients in the first 24 hours after injury were significantly higher than the levels in the control group. In patients who survived the injury, the α-Syn levels tended to be normal after 3 days, while in patients who did not survive, the α-Syn levels in the CSF remained increased until 8 days after the injury [105]. Therefore, the measurement of CSF α-Syn may be a valuable prognostic marker.

Brain trauma leads to the development of PD-related pathology in mice. Interestingly, compared with astrocytes, microglia accumulate a large amount of α-Syn. In Alzheimer’s disease and PD mouse models, bone marrow MSCs, macrophages and microglia were delivered to the brain via the nasal cavity, showing an intracellular amyloid beta (APP/PS1 model) or α-Syn (Thy1-h[A30P]α-Syn model) immune response [106]. In addition, it has been reported that α-Syn aggregation may cause dopaminergic neuron loss or synuclein pathological changes after TBI. These changes occur in the environment of vascular fragility and microglial activation shortly after TBI. Loss of dopaminergic neurons is often accompanied by vascular and immunological changes. IgG exudation was observed in injured rats within 1-2 days, while no IgG exudation was observed in control rats at 7 or 28 days, indicating that blood-brain barrier (BBB) permeability had temporarily increased [107]. Some studies have shown that in astrocytes, α-Syn-induced proinflammatory responses occur in a TLR4-dependent manner [59]. However, unlike inflammatory signals, the uptake of α-Syn by astrocytes is independent of TLR4. *In vitro* studies have shown that the neuroprotective effect of anti-TLR2 antibodies is mediated by preventing α-Syn transmission from neurons to neurons and from neurons to astrocytes; otherwise, the antibodies will promote an NF-κB-dependent proinflammatory response [108]. For example, in the multiple system atrophy model, the activation of astrocytes is directly related to the proximity of α-Syn inclusions in oligodendrocytes, called glial cytoplasmic inclusions [109].

α-Syn stimulates astrocytes; the potential roles of neuroinflammation and neuroprotection and how to establish and maintain an inflammatory microenvironment with this protein are still unknown. Neuronal α-Syn can be directly transferred to astrocytes through sequential exocytosis and endocytosis and induces astrocytes to produce an inflammatory response. Early in the period after cranioencebral injury, the rat TBI model had vascular abnormalities and
inappropriate microglial activation, and the mouse model had dopaminergic neuron loss due to α-Syn and increased microglial activity. The TBI-related changes in α-Syn depend on age and the time after the head injury occurred. For example, after 60 days of TBI in rats, brain tissue was collected and found to be colocalized with α-Syn, tyrosine hydroxylase (TH), an enzyme that synthesizes DA neurons, and the major histocompatibility MHC II. Compared to the control neurons, surviving dopaminergic neurons had significantly reduced TH-positive expression in the dense substantia nigra (SNpc), and the α-Syn accumulation detected in the ipsilateral SN was increased [110]. α-Syn is a pathological link between the chronic effects of TBI and the symptoms of PD, as evidenced by the significant overexpression and abnormal accumulation of α-Syn in the inflammatory SN exposed to chronic TBI [110]. Although microglial and subsequent astrocyte activation is often considered a secondary response to neuronal damage, proinflammatory changes within microglial cells have been observed to cause evidence of injury to DA neurons in PD animal models [109]. There is a difference between the location of neuronal death caused by α-Syn and the differential expression of brain-dependent α-Syn. Expression patterns of α-Syn are different between excitatory and inhibitory hippocampal neurons; α-Syn is highly expressed in neuronal cell bodies in certain early brain regions affected by PD, such as the olfactory bulb, the dorsal motor nucleus of the vagus nerve, and the dense SN. The synaptic expression of α-Syn is mainly accompanied by the expression of the excitatory presynaptic marker vesicle glutamate transporter-1 (VGT-1). In contrast, the capacity of γ-aminobutyrate (GABA) to inhibit the expression of α-Syn in synapses differs among brain regions. α-Syn is clearly expressed in inhibitory synapses in the outer plexiform layer of the olfactory bulb, pale bulb, and SN reticulum but is not expressed in the cerebral cortex, subthalamic nucleus, or thalamus [111]. Similarly, the synaptic expression of α-Syn is mainly accompanied by the expression of VGT-1, an excitatory synaptic marker protein. In contrast, the inhibition of α-Syn expression in synapses differs among brain regions [112]. Another report noted that the diffuse α-Syn proximity connection assay had significantly more signals in the patient group than in the control group, including in the cingulate cortex (1.6-fold increase) and medulla reticulum (6.5-fold increase) [113].

Toxic α-Syn spreads between cells through exosomes and induces apoptosis, and microglia and astrocytes may act as regulators of α-Syn exosome delivery. Exosomes are small vesicles that are released from cells into the extracellular space. The accumulation of α-Syn at the presynaptic end affects several steps of neurotransmitter release. First, high levels of α-Syn change the size of the synaptic vesicle pool and impair its transport, forming exosomes/EVs for distribution to the extracellular space. Second, overexpression of α-Syn may relax or redistribute the protein of the presynaptic SNARE complex, leading to insufficient storage, docking, guidance, and fusion of synaptic vesicles in the active functional area. Third, α-Syn inclusions are found in the presynaptic active area, accompanied by a decrease in protein levels in the active area. In addition, during the recovery of vesicles, overexpression of α-Syn reduces the endocytosis of synaptic vesicle membranes, further impairing the exocytosis of neurotransmitters, which can trigger synaptic dysfunction and impaired neuronal communication [114].

Mechanical stress increases brain Aβ, tau, and α-Syn concentrations in WT mice. The dose-dependent and cumulative effects of repeated mild TBI-induced mechanical stress can trigger and/or accelerate neurodegeneration by causing protein concentrations to exceed disease thresholds [116]. Because axonal damage is related to axonal transport disorders, studies have found that α-Syn accumulation often occurs in the white matter. α-Syn immunoreactivity was found in axonal dystrophy, and axon swelling was found in acute TBI [117]. In addition, a large accumulation of α-Syn was found in swollen axons, and tau protein also accumulated in both axons and neuronal cell bodies [118]. Starting one month after brain infiltration, tau in the prefrontal cortex (PFC) and hippocampus selectively increased for three months, while α-Syn and Hippo increased briefly [119]. In a study by Urya et al., a transient increase in the immunoreactivity of α-Syn in axons that traverse the striatum was observed in adult animals [118]. This accumulation of α-Syn may be the result of abnormal axonal transport and the subsequent accumulation of various proteins at the injured site. In addition, there may be a link between TBI and the oxidative/nitrative stress that produces α-Syn pathology. Impaired neurotransmission has been reported within weeks after experimental TBI, which may also be the cause of behavioral dysfunction. After TBI, the formation of SNARE complexes and the abundance of various SNARE proteins (including CSPα) were reduced [101, 120]. The soluble SNARE complex is a highly
conserved mechanism that promotes vesicle docking and fusion, which is essential for neurotransmission. Overall, these results indicate that abnormal aggregation of multiple proteins occurs in swollen axons after neurodegeneration but that different proteins undergo selective regional aggregation, which may be closely related to functional neuron types and neurotransmitter transmission.

**The Mechanism of α-Syn in Vascular CNS Diseases - Ischemic Stroke**

Cerebral ischemia triggers a complex series of biochemical and molecular events that promote neuronal death and neurological dysfunction. These include but are not limited to excitotoxicity, ion imbalance, edema, oxidative stress, ER stress, and inflammation. After cerebral infarction, a large amount of free radicals and ROS are generated, which promotes the peroxidation of cell membrane lipids and aggravates microcirculation disorder in the ischemic area. The standard treatment for acute cerebral infarction is to improve blood circulation in the cerebral ischemic area as early as possible, improve brain metabolism, and promote the recovery of nerve function. Mitochondria are the main source of ROS (90%), and increased ROS levels due to mitochondrial dysfunction can damage neuronal survival [121]. Neurons in the ischemic penumbra region after cerebral infarction also bear higher loads of ROS and reactive nitrogen species (RNS).

α-Syn is thought to be a chronic neurodegeneration-related protein that can also mediate secondary brain damage after acute brain damage. Neuronal damage due to chronic diseases (such as PD) can continue for years, while that due to acute diseases (such as stroke) continues for hours to days. Stroke can also initiate or accelerate progressive neurodegenerative processes and is a known epidemiological risk factor for AD [122]. α-Syn is mainly distributed in neurons and is permeable to the serosa. In the peripheral blood, a study that detected α-Syn in RBCs suggested that ischemia-reperfusion in stroke patients may destroy cells in the stroke area and make it easier for α-Syn to diffuse into the peripheral blood, which will cause ischemia. The content of α-Syn in the peripheral blood was the highest in the stroke group. The number of α-Syn oligomeric forms in the ischemic stroke group was much higher than that in the PD group, and it has also been revealed that the pathogenesis of ischemic stroke may be correlated to the pathogenesis of PD [123]. In the CNS, Hu et al. showed that hypoxia/ischemia increased the α-Syn protein levels in the rat cerebral cortex [124]. Subsequently, Yoon et al. reported that hippocampal CA1 neuronal loss was more pronounced in adult gerbils than in older gerbils 4 days after ischemia/reperfusion. The α-Syn level in the CA1 region of aged gerbils is higher than that in the CA1 region of adult gerbils, and this result may be related to the early induction of ROS. More importantly, the increase in α-Syn expression and neuronal death can be reduced by treatment with the antioxidant enzyme SOD1, suggesting that ROS promote the expression and aggregation of α-Syn [125]. In addition, different studies have linked the function of α-Syn to mitochondrial fusion, fission, transport, and maintenance.

After cerebral ischemia, the cellular environment, including inflammation, oxidative stress and ER stress, may provide the best conditions for α-Syn aggregation. *In vitro* studies have shown that oxidative/nitrative stress and acidity induce α-Syn oligomerization. These conditions that favor α-Syn fibrosis exist in the ischemic brain and can be used as an *in vivo* model for studying α-Syn aggregation. Middle cerebral artery occlusion (MCAO) in C57BL/6 (Thy1)-h[A30P]α-Syn transgenic mice, which significantly enhances 3-nitrotyrosine immunoreactivity at the congestion site, indicates that nitrification stress may be one of the mechanisms that mediate aggregation toxicity [126]. Therefore, the increased vulnerability of transgenic mice to ischemia suggests that α-Syn aggregates not only form during ischemia but also negatively affect neuronal survival, supporting the view that α-Syn misfolding may be neurotoxic [126]. Interestingly, the use of telmisartan reduced progressive oxidative stress and phosphorylated α-Syn accumulation in stroke-resistant spontaneously hypertensive rats (SHR-SRs) after transient MCAO. Hypertension that persists after tMCAO in SHR-SRs causes long-term oxidative stress, which accelerates the accumulation of p-α-Syn. Telmisartan, a receptor activated by PPARγ, reduces this oxidative stress and the accumulation of p-α-Syn [127]. In addition, Kim et al. found that miR-7 mimic therapy can significantly reduce the induction of α-Syn after ischemia. MiR-7a-5p improves ischemic brain injury by inhibiting α-Syn, and reducing α-Syn can induce mitochondrial fragmentation, oxidative stress and autophagy, thereby reducing neuronal cell death [128].

In addition, global cerebral ischemia in α-Syn KO mice resulted in elevated prostaglandin levels, suggesting that α-Syn may aggravate in mediating postischemic inflammation. Ahmad et al. also demonstrated that stimulation of the prostaglandin D2 receptor DP1 has neuroprotective effects in the ischemic brain in rodents [129]. Another study showed that MCAO-induced transient focal ischemia in adult rats significantly upregulated α-Syn mRNA and protein levels, while
knockdown of α-Syn reduced infarction and promoted better neurological recovery. α-Syn KO also weakened known ischemic pathological markers, including markers of mitochondrial dysfunction (dynamin-related protein 1, Drp1), apoptosis (cleaved caspase-3), autophagy (LC-3 II/I ratio), and oxidative stress (3-nitrotyrosine). In addition, the α-Syn protein is oligomerized, aggregated and translocated to the nucleus of neurons after stroke in rats and humans [122]. Adult rats suffered moderate ischemia-reperfusion injury, leading to α-Syn induction and phosphorylation and nuclear translocation of α-Syn and p-Ser-129, resulting in α-Syn aggregates; in addition, 4 months later, the animals formed aggregates of proteinase K [130]. After toxic injury, α-Syn translocates into the neuronal nucleus and forms a complex with histones, leading to a reduction in histone acetylation. α-Syn overexpression is thought to increase Drp1 translocation and alter mitochondrial morphology through extracellular signal-regulated kinases [131]. In addition, α-Syn forms an oligomer with a ring-like, porous structure in the membrane, which has high permeability to calcium, leading to caspase activation and death of apoptotic neurons. Overexpression of WT α-Syn caused impaired macroautophagy through Rab1a inhibition [132]. In conclusion, α-Syn is a potential therapeutic target for reducing brain damage after stroke.

### Summary and Future Prospects

We separately summarized different aspects of traumatic CNS disease and stroke, from the structural and physiological features of α-Syn to its pathological processes and disease outcomes. The structural characteristics and membrane positioning of the amphiphilic and hydrophobic α-Syn monomer control its stability in the membrane, transmembrane transport of substances, and transmission of neurotransmitters. When the body is damaged, α-Syn aggregates abnormally, causing mitochondrial dysfunction, abnormal lysosomal function, exacerbated oxidative stress, free radical damage, and a series of inflammatory cascades. Eventually, related neuronal death results in abnormal or restricted neurotransmission (dopaminergic and cholinergic neurons).

Based on this, there are still many unresolved questions about the effects of α-Syn on traumatic and vascular CNS diseases:

1. Based on the existing research, we are aware of the neurotoxic effects of α-Syn after injury, but what is the physiological effect of α-Syn on injury?
2. CNS injury is accompanied by neuroinflammation and α-Syn aggregation or upregulation. Does inflammation promote α-Syn aggregation or does α-Syn aggregation promote inflammation? Research has revealed that α-Syn is not unique to neurons but is also localized in glial cells (such as microglia, astrocytes and oligodendrocytes). However, what kind of glial cells does α-Syn affect during the secondary inflammatory response to CNS injury?

3. α-Syn is not only the most abundant protein in the CNS but also exists in the peripheral blood and peripheral nervous system. However, many studies have found that the expression of α-Syn in the peripheral blood or CSF increases and acts as a biomarker for diseases (such as SCI, TBI, and stroke). The most notable feature of traumatic CNS disease is the BBB, and the cerebrospinal barrier is damaged. Does this occur because α-Syn migrates to the peripheral blood or because local α-Syn monomers accumulate?

4. The mechanism by which α-Syn is transmitted between cells is still unknown, and whether transmission is related to the vagus nerve currently remains unclear.

First, an injury related to trauma or stroke is a serious blow to the CNS that triggers a series of abnormal pathological reactions. The overexpression and aggregation of α-Syn after injury is likely to cause the death of related neurons, such as autonomic neurons and residual neurons at the edge of the injury. It may be difficult for α-Syn to perform its physiological functions due to environmental damage. In early undamaged cells, α-Syn still performs physiological functions such as transmembrane transport, membrane stability, and precise release of neurotransmitters. The inflammatory response is the main change during the acute phase of injury. It occurs immediately after the injury. At this time, α-Syn aggregation or overexpression is very low or almost negligible; the inflammatory response decreases over time, but many studies have found that during the chronic phase of the disease, a large amount of α-Syn aggregation occurs in old age, so it is closely related to neurodegenerative diseases. Therefore, α-Syn aggregation showed a time-dependent increase after injury. In existing studies, α-Syn was found in microglia, astrocytes and oligodendrocytes. Clinically, due to ethical issues related to the use of patients' blood, an increase in α-Syn was detected in the cerebrospinal fluid. In animal experiments, α-Syn overexpression was found in a substantial portion of the injured area. We believe that the source of α-Syn may be related to the course of the disease, that it is difficult to determine the main source, and that central and peripheral blood sources may exist at the same time. From a macro perspective, we currently believe that α-Syn is likely to propagate along
the autonomic nervous system because this type of nerve is unmyelinated, the axons are thin and wide, and the cell body has a high energy load. Since this remains an unexplored question, the answer is definitely complicated.

**Abbreviations**

α-Syn: α-Synuclein; IDP: inherently disordered protein; PD: Parkinson disease; NTD: N-terminal domain; CTD: C-terminal domain; SNARE: soluble NSF attachment protein receptor; CSF: cerebrospinal fluid; EVs: extracellular vesicles; DA: dopamine; CSPα: cysteine choline protein α; ER: endoplasmic reticulum; VDACs: voltage-dependent anion channels; SN: substantia nigra; HDL: high-density lipoprotein; ROS: reactive oxygen species; RNS: reactive nitrogen species; PTM: Post-translational modification; Ser-129: Serine-129; PLK2: Polo-like kinase 2; PP2A: Protein phosphatase 2; SDS: sodium lauryl sulfate; UPS: ubiquitin proteasome system; ALP: autophagy lysosomal pathway; AGEs: advanced glycosylation end products; LB: Lewy bodies; AD: autonomic dysfunction; GCase: glucocerebrosidase; CNS: central nervous system; LC3B: light chain 3B; FCγR: Fc-γ receptors; TLR: Toll-like receptor; TNF-α: tumor necrosis factor-α; IL: interleukin; MCP-1: monocyte chemoattractic protein-1; IFN: interferon; iNOS: inducible nitric oxide synthase; Arg1: arginase 1; MSCs: mesenchymal stem cells; GABA: γ-aminobutyrate; VGT-1: vesicle glutamate transporter-1; SCI: spinal cord injury; HIF-1α: hypoxia-inducible factors-1α; CNTF: ciliary neurotrophic factor; Chrnb2: nicotinic cholinergic receptor subtype 2; Chrm2: muscarinic cholinergic receptor β2; TBI: Traumatic brain injury; CTE: chronic traumatic encephalopathy; BBB: Blood-brain barrier; TH: tyrosine hydroxylase; SNpc: dense substancia nigra; Aβ: amyloid β; MCAO: middle cerebral artery occlusion; PPARγ: peroxisome proliferator-activated receptor γ; KO: knockout; Drp1: dynamin-related protein 1.

**AUTHOR CONTRIBUTIONS**

This manuscript was drafted by HZ, YYY, and MWZ. All other authors critically commented the manuscript and approved the final manuscript.

**ACKNOWLEDGMENTS**

We are grateful for the technical support provided by Peking University Third Hospital Central Laboratory.

**CONFLICTS OF INTEREST**

The authors declare no conflicts of interest.

**FUNDING**

This work was funded by the National Natural Science Foundation of China (NO.11472018 to MW. Zhou). We also thank the Young Scientist fund of the National Natural Science Foundation of China for financial support (NO. 1150020073 to N. Liu).

**REFERENCES**

1. Mor DE, Ugras SE, Daniels MJ, Ischiropoulos H. Dynamic structural flexibility of α-synuclein. Neurobiol Dis. 2016; 88:66–74. [PMID: 26747212](https://doi.org/10.1016/j.nbd.2015.12.018)

2. Guhathakurta S, Bok E, Evangelista BA, Kim YS. Deregulation of α-synuclein in Parkinson’s disease: insight from epigenetic structure and transcriptional regulation of SNCA. Prog Neurobiol. 2017; 154:21–36. [PMID: 28445713](https://doi.org/10.1016/j.pneurobio.2017.04.004)

3. Galvagnion C. The role of lipids interacting with α-synuclein in the pathogenesis of Parkinson’s disease. J Parkinsons Dis. 2017; 7:433–50. [PMID: 28671142](https://doi.org/10.3233/JPD-171103)

4. Saraiva MA, Jorge CD, Santos H, Maçanita AL. Earliest events in α-synuclein fibrillation probed with the fluorescence of intrinsic tyrosines. J Photochem Photobiol B. 2016; 154:16–23. [PMID: 26613347](https://doi.org/10.1016/j.jphotobiol.2015.11.006)

5. Muntané G, Ferrer I, Martinez-Vicente M. A-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience. 2012; 200:106–19. [PMID: 22079575](https://doi.org/10.1016/j.neuroscience.2011.10.042)

6. Fauvet B, Mbefo MK, Fares MB, Desobry C, Michael S, Ardah MT, Tisika E, Coune P, Prudent M, Lion N, Eliezer D, Moore DJ, Schneider B, et al. A-synuclein in central nervous system and from erythrocytes, mammalian cells, and escherichia coli exists predominantly as disordered monomer. J Biol Chem. 2012; 287:15345–64. [PMID: 22315227](https://doi.org/10.1074/jbc.M111.318949)

7. Bartels T, Choi JG, Selkoe DJ. A-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 2011; 477:107–10. [PMID: 21841800](https://doi.org/10.1038/nature10324)

8. Gaugler MN, Genc O, Bobela W, Mohanna S, Ardah...
9. Vicario M, Cieri D, Brini M, Cali T. The close encounter between alpha-synuclein and mitochondria. Front Neurosci. 2018; 12:388. https://doi.org/10.3389/fnins.2018.00388 PMID: 29930495

10. Prots I, Veber V, Brey S, Campioni S, Buder K, Riek R, Böhm KJ, Winner B. A-synuclein oligomers impair neuronal microtubule-kinesin interplay. J Biol Chem. 2013; 288:21742–54. https://doi.org/10.1074/jbc.M113.451815 PMID: 23744071

11. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci. 2000; 20:3214–20. https://doi.org/10.1523/JNEUROSCI.20-09-03214.2000 PMID: 10777786

12. Horrocks MH, Lee SF, Gandhi S, Magdalinou NK, Chen SW, Devine MJ, Tosatto L, Kjaergaard M, Beckwith JS, Zetterberg H, Iljina M, Cremades N, Dobson CM, et al. Single-molecule imaging of individual amyloid protein aggregates in human biofluids. ACS Chem Neurosci. 2016; 7:399–406. https://doi.org/10.1021/acschemneuro.5b00324 PMID: 26800462

13. Gustafsson G, Lööv C, Persson E, Lázaró DF, Takeda S, Bergström J, Erlandsson A, Sehlin D, Balaj L, György B, Hallbeck M, Outeiro TF, Breakefield XO, et al. Secretion and uptake of α-synuclein via the presynaptic vesicles in cultured cells. Cell Mol Neurobiol. 2018; 38:1539–50. https://doi.org/10.1007/s10571-018-0622-5 PMID: 30288631

14. Lautenschläger J, Kaminski CF, Kaminski Schierle GS. α-synuclein - regulator of exocytosis, endocytosis, or both? Trends Cell Biol. 2017; 27:468–79. https://doi.org/10.1016/j.tcb.2017.02.002 PMID: 28259601

15. Sambri I, D’Alessio R, Ezhova Y, Giuliano T, Sorrentino NC, Cacace V, De Risi M, Cataldi M, Annunziato L, De Leonibus E, Fraldi A. Lysosomal dysfunction disrupts presynaptic maintenance and restoration of presynaptic function prevents neurodegeneration in lysosomal storage diseases. EMBO Mol Med. 2017; 9:112–32. https://doi.org/10.15252/emmm.201606965 PMID: 27881461

16. Fusco G, Sanz-Hernandez M, De Simone A. Order and disorder in the physiological membrane binding of α-synuclein. Curr Opin Struct Biol. 2018; 48:49–57. https://doi.org/10.1016/j.sbi.2017.09.004 PMID: 29100107

17. Dikiy I, Eliezer D. N-terminal acetylation stabilizes n-terminal helicity in lipid- and micelle-bound α-synuclein and increases its affinity for physiological membranes. J Biol Chem. 2014; 289:3652–65. https://doi.org/10.1074/jbc.M113.512459 PMID: 24338013

18. Ganguly U, Chakrabarti SS, Kaur U, Mukherjee A, Chakrabarti S. Alpha-synuclein, proteotoxicity and Parkinson’s disease: search for neuroprotective therapy. Curr Neuropharmacol. 2016; 18:1086–97. https://doi.org/10.2174/1570159X15666171129100944 PMID: 29189163

19. Stefanovic AN, Stöckl MT, Claessens MM, Subramaniam V. A-synuclein oligomers distinctively permeabilize complex model membranes. FEBS J. 2014; 281:2838–50. https://doi.org/10.1111/febs.12824 PMID: 24767583

20. Feng ST, Wang ZZ, Yuan YH, Wang XL, Sun HM, Chen NH, Zhang Y. Dynamin-related protein 1: a protein critical for mitochondrial fission, mitophagy, and neuronal death in Parkinson’s disease. Pharmacol Res. 2020; 151:104553. https://doi.org/10.1016/j.phrs.2019.104553 PMID: 31760107

21. Paillusson S, Gomez-Suaga P, Stoica R, Little D, Gissen P, Devine MJ, Noble W, Hanger DP, Miller CC. A-synuclein binds to the ER-mitochondria tethering protein VAPB to disrupt Ca\(^{2+}\) homeostasis and mitochondrial ATP production. Acta Neuropathol. 2017; 134:129–49. https://doi.org/10.1007/s00401-017-1704-z PMID: 28337542

22. Ludtmann MH, Angelova PR, Ninkina NN, Gandhi S, Buchman VL, Abramov AY. Monomeric alpha-synuclein exerts a physiological role on brain ATP synthase. J Neurosci. 2016; 36:10510–21. https://doi.org/10.1523/JNEUROSCI.1659-16.2016 PMID: 27733604

23. Rostovtseva TK, Gurnev PA, Protchenko O, Hoogerheide DP, Yap TL, Phlipott CC, Lee JC, Bezrukov SM. A-synuclein shows high affinity interaction with voltage-dependent anion channel, suggesting mechanisms of mitochondrial regulation and toxicity in Parkinson disease. J Biol Chem. 2015; 290:18467–77.
24. Harishandra DS, Jin H, Anantharam V, Kanthesamy A, Kanthesamy AG. A-synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson’s disease. Toxicol Sci. 2015; 143:454–68. https://doi.org/10.1093/toxsci/kfu247 PMID:25416158

25. Hsiao JT, Halliday GM, Kim WS. A-synuclein regulates neuronal cholesterol efflux. Molecules. 2017; 22:1769. https://doi.org/10.3390/molecules22101769 PMID:29048372

26. Eichmann C, Kumari P, Riek R. High-density lipoprotein-like particle formation of synuclein variants. FEBS Lett. 2017; 591:304–11. https://doi.org/10.1002/1873-3468.12543 PMID:28027392

27. Rosborough K, Patel N, Kalia LV. A-synuclein and parkinsonism: updates and future perspectives. Curr Neurol Neurosci Rep. 2017; 17:31. https://doi.org/10.1007/s11910-017-0737-y PMID:28324300

28. Lv Z, Krasnoslobodtsev AV, Zhang Y, Ysselstein D, Rochet JC, Blanchard SC, Lyubchenko YL. Effect of acidic pH on the stability of α-synuclein dimers. Biopolymers. 2016; 105:715–28. https://doi.org/10.1002/bip.22874 PMID:27177831

29. Ranjan P, Kumar A. Perturbation in long-range contacts modulates the kinetics of amyloid formation in α-synuclein familial mutants. ACS Chem Neurosci. 2017; 8:2235–46. https://doi.org/10.1021/acschemneuro.7b00149 PMID:28759722

30. Lv Z, Krasnoslobodtsev AV, Zhang Y, Ysselstein D, Rochet JC, Blanchard SC, Lyubchenko YL. Direct detection of α-synuclein dimerization dynamics: single-molecule fluorescence analysis. Biophys J. 2015; 108:2038–47. https://doi.org/10.1016/j.bpj.2015.03.010 PMID:25902443

31. Zhang T, Tian Y, Li Z, Liu S, Hu X, Yang Z, Ling X, Liu S, Zhang J. Molecular dynamics study to investigate the dimeric structure of the full-length α-synuclein in aqueous solution. J Chem Inf Model. 2017; 57:2281–93. https://doi.org/10.1021/acs.jcim.7b00210 PMID:28796507

32. Colom-Cadena M, Pegoerues J, Herrmann AG, Henstridge CM, Muñoz L, Querol-Vilaseca M, Martín-Paniello CS, Luque-Cabeceras J, Clarimon J, Belbin O, Núñez-Llaves R, Blesa R, Smith C, et al. Synaptic phosphorylated α-synuclein in dementia with lewy bodies. Brain. 2017; 140:3204–14. https://doi.org/10.1093/brain/awx275 PMID:29177427

33. Games D, Seubert P, Rockenstein E, Patrick C, Trejo M, Ubhi K, Ettle B, Ghassemian M, Barbour R, Schenk D, Nuber S, Masliah E. Axonopathy in an α-synuclein transgenic model of lewy body disease is associated with extensive accumulation of c-terminal-truncated α-synuclein. Am J Pathol. 2013; 182:940–53. https://doi.org/10.1016/j.ajpath.2012.11.018 PMID:23313024

34. Liu C, Fei E, Jia N, Wang H, Tao R, Iwata A, Nukina N, Zhou J, Wang G. Assembly of lysine 63-linked ubiquitin conjugates by phosphorylated alpha-synuclein implies lewy body biogenesis. J Biol Chem. 2007; 282:14558–66. https://doi.org/10.1074/jbc.M700422200 PMID:17360705

35. Barinova KV, Kuravsky ML, Arutyunyan AM, Serebryakova MV, Schmalhausen EV, Muronetz VI. Dimerization of Tyr136Cys alpha-synuclein prevents amyloid transformation of wild type alpha-synuclein. Int J Biol Macromol. 2017; 96:35–43. https://doi.org/10.1016/j.ijbiomac.2016.12.011 PMID:27939273

36. Souza JM, Giasson BI, Chen Q, Lee VM, Ischiropoulos H. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem. 2000; 275:18344–49. https://doi.org/10.1074/jbc.M000206200 PMID:10747881

37. Tofaris GK, Kim HT, Hourez R, Jung JW, Kim KP, Goldberg AL. Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway. Proc Natl Acad Sci USA. 2011; 108:17004–09. https://doi.org/10.1073/pnas.1109356108 PMID:21953697

38. Xilouri M, Brekk OR, Stefanis L. A-synuclein and protein degradation systems: a reciprocal relationship. Mol Neurobiol. 2013; 47:537–83. https://doi.org/10.1007/s12035-012-8341-2 PMID:22941029

39. Vicente Miranda H, El-Agnaf OM, Outeiro TF. Glycation in Parkinson’s disease and Alzheimer’s disease. Mov Disord. 2016; 31:782–90. https://doi.org/10.1002/mds.26566 PMID:26946341

40. Willingham S, Outeiro TF, DeVit MJ, Lindquist SL, Muchowski PJ. Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein.
41. Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm (Vienna). 1997; 104:661–77. https://doi.org/10.1007/BF01291884 PMID:944566

42. Vicente Miranda H, Szego ÉM, Oliveira LM, Breda C, Darenfelbiglo E, de Oliveira RM, Ferreira DG, Gomes MA, Rott R, Oliveira M, Munari F, Enguita FJ, Simões T, et al. Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies. Brain. 2017; 140:1399–419. https://doi.org/10.1093/brain/awx056 PMID:28398476

43. Hung WY, Mold DE, Tourian A. Huntington's-chorea fibroblasts. Cellular protein glycosylation. Biochem J. 1980; 190:711–19. https://doi.org/10.1042/bj1900711 PMID:6451218

44. Izumi Y, Kondo N, Takahashi R, Akaie A, Kume T. Reduction of immunoreactivity against the c-terminal region of the intracellular α-synuclein by exogenous α-synuclein aggregates: possibility of conformational changes. J Parkinsons Dis. 2016; 6:569–79. https://doi.org/10.3233/JPD-160835 PMID:27314756

45. Binolfi A, Limatola A, Verzini S, Kosten J, Theillet FX, Rose HM, Bekei B, Stuiver M, van Rossum M, Selenko P. Intracellular repair of oxidation-damaged α-synuclein fails to target c-terminal modification sites. Nat Commun. 2016; 7:10251. https://doi.org/10.1038/ncomms10251 PMID:26807843

46. Ma L, Yang C, Zhang X, Li Y, Wang S, Zheng L, Huang K. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-synuclein: a vicious cycle in Parkinson’s disease. Biochim Biophys Acta Mol Basis Dis. 2018; 1864:3714–25. https://doi.org/10.1016/j.bbbadis.2018.10.003 PMID:30290273

47. McGlinchey RP, Lacy SM, Huffer KE, Tayebi N, Sidransky E, Lee JC. C-terminal α-synuclein truncations are linked to cysteine cathepsin activity in Parkinson’s disease. J Biol Chem. 2019; 294:9973–84. https://doi.org/10.1074/jbc.RA119.008930 PMID:31092553

48. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of α-synuclein in neurological disorders. Lancet Neurol. 2011; 10:1015–25. https://doi.org/10.1016/S1474-4422(11)70213-7 PMID:22014436

49. Ordonez DG, Lee MK, Feany MB. A-synuclein induces mitochondrial dysfunction through spectrin and the actin cytoskeleton. Neuron. 2018; 97:108–24.e6. https://doi.org/10.1016/j.neuron.2017.11.036 PMID:29242985

50. Högl B, Stefani A, Videnovic A. Idiopathic REM sleep behaviour disorder and neurodegeneration - an update. Nat Rev Neurol. 2018; 14:40–55. https://doi.org/10.1038/nrneurol.2017.157 PMID:29170501

51. Lee HJ, Cho ED, Lee KW, Kim JH, Cho SG, Lee SJ. Autophagic failure promotes the exocytosis and intercellular transfer of α-synuclein. Exp Mol Med. 2013; 45:e22. https://doi.org/10.1038/emm.2013.45 PMID:23661100

52. Wong YC, Krainc D. A-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med. 2017; 23:1–13. https://doi.org/10.1038/nm.4269 PMID:28170377

53. Wang S, Chu CH, Guo M, Jiang L, Nie H, Zhang W, Wilson B, Yang L, Stewart T, Hong JS, Zhang J. Identification of a specific α-synuclein peptide (α-syn 29-40) capable of eliciting microglial superoxide production to damage dopaminergic neurons. J Neuroinflammation. 2016; 13:158. https://doi.org/10.1186/s12974-016-0606-7 PMID:27329107

54. Zhang S, Eitan E, Wu TY, Mattson MP. Intercellular transfer of pathogenic α-synuclein by extracellular vesicles is induced by the lipid peroxidation product 4-hydroxynonenal. Neurobiol Aging. 2018; 61:52–65. https://doi.org/10.1016/j.neurobiolaging.2017.09.016 PMID:29035751

55. Nakamura T, Lipton SA. Molecular mechanisms of nitrosative stress-mediated protein misfolding in neurodegenerative diseases. Cell Mol Life Sci. 2007; 64:1609–20. https://doi.org/10.1007/s00018-007-6525-0 PMID:17453143

56. Kumar A, Ganini D, Mason RP. Role of cytochrome c in α-synuclein radical formation: implications of α-synuclein in neuronal death in maneb- and paraquat-induced model of Parkinson’s disease. Mol Neurodegener. 2016; 11:70. https://doi.org/10.1186/s13024-016-0135-y PMID:27884192

57. Harms AS, Delic V, Thome AD, Bryant N, Liu Z, Chandra S, Jurkuvanaite A, West AB. A-synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration. Acta Neuropathol
omic analysis of α-synuclein and adaptive immunity in Parkinson disease. J Parkinsons Dis. 2015; 5:1–19. 
https://doi.org/10.3233/JPD-140491 PMID:25588354

59. Rannikko EH, Weber SS, Kahle PJ. Exogenous α-synuclein induces toll-like receptor 4 dependent inflammatory responses in astrocytes. BMC Neurosci. 2015; 16:57. 
https://doi.org/10.1186/s12868-015-0192-0 PMID:26346361

60. Dietz V, Fouad K. Restoration of sensorimotor functions after spinal cord injury. Brain. 2014; 137:654–67. 
https://doi.org/10.1093/brain/awt262 PMID:24103913

61. Kjell J, Olson L. Rat models of spinal cord injury: from pathology to potential therapies. Dis Model Mech. 2016; 9:1125–37. 
https://doi.org/10.1242/dmm.025833 PMID:27736748

62. Ahuja CS, Noris S, Tetreault L, Wilson J, Kwon B, Harrop J, Choi D, Fehlings MG. Traumatic spinal cord injury-repair and regeneration. Neurosurgery. 2017; 80:S9–22. 
https://doi.org/10.1093/neuros/nyw080 PMID:28350947

63. Dai J, Xu LJ, Han GD, Sun HL, Zhu GT, Jiang HT, Yu GY, Tang XM. MiR-137 attenuates spinal cord injury by modulating NEUROD4 through reducing inflammation and oxidative stress. Eur Rev Med Pharmacol Sci. 2018; 22:1884–90. 
https://doi.org/10.26355/eurrev_201804_14709 PMID:29687839

64. David S, Kroner A. Repertoire of microglial and macrophage responses after spinal cord injury. Nat Rev Neurosci. 2011; 12:388–99. 
https://doi.org/10.1038/nrn3053 PMID:21673720

65. Zeng H, Yu BF, Liu N, Yang YY, Xing HY, Liu XX, Zhou MW. Transcriptomic analysis of α-synuclein knockdown after T3 spinal cord injury in rats. BMC Genomics. 2019; 20:851. 
https://doi.org/10.1186/s12864-019-6244-6 PMID:31726970

66. Liddelow SA, Barres BA. Reactive astrocytes: production, function, and therapeutic potential. Immunity. 2017; 46:957–67. 
https://doi.org/10.1016/j.immuni.2017.06.006 PMID:28636962

67. Bergeron M, Motter R, Tanaka P, Fauss D, Babcock M, Chiou SS, Nelson S, San Pablo F, Anderson JP. In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain. Neuroscience. 2014; 256:72–82. 
https://doi.org/10.1016/j.neuroscience.2013.09.061 PMID:24128992

68. McCormack AL, Mak SK, Di Monte DA. Increased α-synuclein phosphorylation and nitration in the aging primate substantia nigra. Cell Death Dis. 2012; 3:e315. 
https://doi.org/10.1038/cddis.2012.50 PMID:22647852

69. Sato H, Arawaka S, Hara S, Fukushima S, Koga K, Koyama S, Kato T. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson’s disease. J Neurosci. 2011; 31:16884–94. 
https://doi.org/10.1523/JNEUROSCI.3967-11.2011 PMID:22090514

70. Pérez-Revuelta BI, Hettich MM, Ciociaro A, Rotermund C, Kahle PJ, Krauss S, Di Monte DA. Metformin lowers ser129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation. Cell Death Dis. 2014; 5:e1209. 
https://doi.org/10.1038/cddis.2014.175 PMID:24810045

71. Arawaka S, Sato H, Sasaki A, Koyama S, Kato T. Mechanisms underlying extensive Ser129 phosphorylation in α-synuclein aggregates. Acta Neuropathol Commun. 2017; 5:99. 
https://doi.org/10.1186/s40478-016-0452-6 PMID:28619113

72. Zeng H, Liu N, Yang YY, Xing HY, Liu XX, Li F, La GY, Huang MJ, Zhou MW. Lentivirus-mediated downregulation of α-synuclein reduces neuroinflammation and promotes functional recovery in rats with spinal cord injury. J Neuroinflammation. 2019; 16:283. 
https://doi.org/10.1186/s12974-019-1658-2 PMID:3188724

73. Qiao H, Zhang Q, Yuan H, Li Y, Wang D, Wang R, He X. Elevated neuronal α-synuclein promotes microglia activation after spinal cord ischemic/reperfused injury. Neuroporrt. 2015; 26:656–61. 
https://doi.org/10.1097/WNR.0000000000000406 PMID:26103121

74. Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, Joong Lee S, Masliah E, Hwang D, Lee HJ, Lee SJ. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun. 2013; 4:1562. 
https://doi.org/10.1038/ncomms2534 PMID:23463005
75. Lim S, Kim HJ, Kim DK, Lee SJ. Non-cell-autonomous actions of α-synuclein: implications in glial synucleinopathies. Prog Neurobiol. 2018; 169:158–71. https://doi.org/10.1016/j.pneurobio.2018.06.010 PMID:30173732

76. Qiao H, He X, Zhang Q, Zhang N, Li L, Hui Y, Li W, Wang D, Wu Z. A-synuclein induces microglial cell migration through stimulating HIF-1α accumulation. J Neurosci Res. 2017; 95:1809–17. https://doi.org/10.1002/jnr.24012 PMID:28134982

77. Qiao H, He X, Zhang Q, Yuan H, Wang D, Li L, Hui Y, Wu Z, Li W, Zhang N. Alpha-synuclein induces microglial migration via PKM2-dependent glycolysis. Int J Biol Macromol. 2019; 129:601–07. https://doi.org/10.1016/j.ijbiomac.2019.02.029 PMID:30738168

78. Sakurai M, Kawamura T, Nishimura H, Suzuki H, Tezuka F, Abe K. Induction of Parkinson disease-related proteins in motor neurons after transient spinal cord ischemia in rabbits. J Cereb Blood Flow Metab. 2009; 29:752–58. https://doi.org/10.1038/jcbfm.2008.167 PMID:19142195

79. Reynolds AD, Glanzer JG, Kadiu I, Ricardo AG, Arranz R, Ness S, Roodveldt C, Guilliams T, De-Genst EJ, Klenerman D, Wood NW, Knowles TP, et al. Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation. Proc Natl Acad Sci USA. 2015; 112:E1994–2003. https://doi.org/10.1073/pnas.1421204112 PMID:25855634

80. Tyson T, Steiner JA, Brundin P. Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology. J Neurochem. 2016 (Suppl 1); 139:275–89. https://doi.org/10.1111/jnc.13449 PMID:26617280

81. Chaudhuri A, Ciborowski P, Cerny R, Gelman B, Thomason L, Houlden H. Autonomic dysfunction in genetic forms of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007; 78:597–601. https://doi.org/10.1136/jnnp.2006.107871 PMID:17518921

82. Fu H, Liu B, Frost JL, Hong S, Jin M, Ostaszewski B, Shankar GM, Costantino IM, Carroll MC, Mayadas TN, Lemere CA. Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar Aβ by microglia. Glia. 2012; 60:993–1003. https://doi.org/10.1002/glia.22331 PMID:22438044

83. Rodríguez-Perez AI, Sucunza D, Pedrosa MA, Garrido-Gil P, Kulisevsky J, Lanciego JL, Labandeira-Garcia JL. Angiotensin type 1 receptor antagonists protect against alpha-synuclein-induced neuroinflammation and dopaminergic neuron death. Neurotherapeutics. 2018; 15:1063–81. https://doi.org/10.1007/s13311-018-0646-z PMID:29987762

84. Park HJ, Oh SH, Kim HN, Jung YJ, Lee PH. Mesenchymal stem cells enhance α-synuclein clearance via M2 microglia polarization in experimental and human parkinsonian disorder. Acta Neuropathol. 2016; 132:685–701. https://doi.org/10.1007/s00401-016-1605-6 PMID:27497943

85. Chen SW, Drakulic S, Des E, Ouberai M, Aprile FA, Arranz R, Ness S, Roodveldt C, Guilliams T, De-Genst EJ, Klenerman D, Wood NW, Knowles TP, et al. Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation. Proc Natl Acad Sci USA. 2015; 112:E1994–2003. https://doi.org/10.1073/pnas.1421204112 PMID:25855634

86. Del Tredici K, Braak H. Review: sporadic Parkinson’s disease: development and distribution of α-synuclein pathology. Neuropathol Appl Neurobiol. 2016; 42:33–50. https://doi.org/10.1111/nan.12298 PMID:27497943

87. Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, Lee JH, Kim WR, Kook M, Foss CA, Shen C, Lee H, Kulkarni S, et al. Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease. Neuron. 2019; 103:627–641.e7. https://doi.org/10.1016/j.neuron.2019.05.035 PMID:31255487

88. Genst EJ, Arranz R, Ness S, Provost MC, Guilliams T, De-Genst EJ, Klenerman D, Wood NW, Knowles TP, et al. Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation. Proc Natl Acad Sci USA. 2015; 112:E1994–2003. https://doi.org/10.1073/pnas.1421204112 PMID:25855634

89. Del Tredici K, Braak H. Review: sporadic Parkinson’s disease: development and distribution of α-synuclein pathology. Neuropathol Appl Neurobiol. 2016; 42:33–50. https://doi.org/10.1111/nan.12298 PMID:26662475

90. Kumar P, Pillay V, Choonara YE, Modi G, Naidoo D, du Toit LC. In silico theoretical molecular modeling for Alzheimer’s disease: the nicotine-curcumin paradigm in neuroprotection and neurotherapy. Int J Mol Sci. 2011; 12:694–724. https://doi.org/10.3390/ijms12010694 PMID:21340009

91. Chelban V, Vichayanrat E, Schottlaende L, Iodice V, Houlden H. Autonomic dysfunction in genetic forms of synucleinopathies. Mov Disord. 2018; 33:359–71. https://doi.org/10.1002/mds.27343 PMID:29508456
Jaimez M, Kirstein M, Alborch E, Fariñas I, Pérez-Sánchez F. Perivascular nerve fiber α-synuclein regulates contractility of mouse aorta: a link to autonomic dysfunction in Parkinson’s disease. Neurochem Int. 2010; 56:991–98. https://doi.org/10.1016/j.neu interf.2010.04.011 PMID:20420875

92. Feng GY, Liu J, Wang YC, Wang ZY, Hu Y, Xia OJ, Xu Y, Shang FF, Chen MR, Wang F, Zhou X, Wang TH. Effects of alpha-synuclein on primary spinal cord neurons associated with apoptosis and CNTF expression. Cell Mol Neurobiol. 2017; 37:817–29. https://doi.org/10.1007/s10571-016-0420-x PMID:27581683

93. Alabi AO, Ajayi AM, Ben-Azu B, Bakre AG, Umukoro S. Methyl jasmonate abrogates rotenone-induced parkinsonian-like symptoms through inhibition of oxidative stress, release of pro-inflammatory cytokines, and down-regulation of immnospositive cells of NF-kB and α-synuclein expressions in mice. Neurotoxicology. 2019; 74:172–83. https://doi.org/10.1016/j.nuro.2019.07.003 PMID:31336111

94. Anusha C, Sumathi T, Joseph LD. Protective role of apigenin on rotenone induced rat model of Parkinson’s disease: suppression of neuroinflammation and oxidative stress mediated apoptosis. Chem Biol Interact. 2017; 269:67–79. https://doi.org/10.1016/j.cbi.2017.03.016 PMID:28389404

95. Wang L, Hong J, Wu Y, Liu G, Yu W, Chen L. Seipin deficiency in mice causes loss of dopaminergic neurons via aggregation and phosphorylation of α-synuclein and neuroinflammation. Cell Death Dis. 2018; 9:440. https://doi.org/10.1038/s41419-018-0471-7 PMID:29670081

96. Whiten DR, Cox D, Horrocks MH, Taylor CG, De S, Flagmeier P, Tosatto L, Kumira JR, Ecroyd H, Dobson CM, Klenerman D, Wilson MR. Single-molecule characterization of the interactions between extracellular chaperones and toxic α-synuclein oligomers. Cell Rep. 2018; 23:3492–500. https://doi.org/10.1016/j.celrep.2018.05.074 PMID:29924993

97. Farrand AQ, Helke KL, Gregory RA, Gooz M, Hinson VK, Boger HA. Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson’s disease. Brain Stimul. 2017; 10:1045–54. https://doi.org/10.1016/j.brs.2017.08.008 PMID:28918943

98. Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, Zago W, Ness DK, Griffith SG, Grundman M, Soto J, Ostrowitzki S, Boess FG, et al. Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-α-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurol. 2018; 75:1206–14. https://doi.org/10.1001/jamaneurol.2018.1487 PMID:29913017

99. Pearn ML, Niesman IR, Egawa J, Sawada A, Almenar-Queralt A, Shah SB, Duckworth JL, Head BP. Pathophysiology associated with traumatic brain injury: current treatments and potential novel therapeutics. Cell Mol Neurobiol. 2017; 37:571–85. https://doi.org/10.1007/s10571-016-0400-1 PMID:27383839

100. Genrikhs EE, Voronkov DN, Kapkaeva MR, Isaev NK, Stelmashook EV. Focal unilateral traumatic brain injury causes delayed neurodegenerative changes in the brain of rats. Bull Exp Biol Med. 2017; 164:211–13. https://doi.org/10.1007/s10517-017-3960-2 PMID:29177900

101. Carlson SW, Dixon CE. Lithium improves dopaminergic neurotransmission and increases dopaminergic protein abundance in the striatum after traumatic brain injury. J Neurotrauma. 2018; 35:2827–36. https://doi.org/10.1089/neu.2017.5509 PMID:29699444

102. McKee AC, Stern RA, Nowinski CJ, Stein TD, Alvarez VE, Daneshvar DH, Lee HS, Wojtowicz SM, Hall G, Baugh CM, Riley DO, Kubiats LA, Cormier KA, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013; 136:43–64. https://doi.org/10.1093/brain/aws307 PMID:23208308

103. Mondello S, Buki A, Italian D, Jeromin A. A-synuclein in CSF of patients with severe traumatic brain injury. Neurology. 2013; 80:1662–68. https://doi.org/10.1212/WNL.0b013e3182904d43 PMID:23553480

104. Ikonomovic MD, Abrahamsson EE, Carlson SW, Graham SH, Dixon CE. Novel therapies for combating chronic neuropathological sequelae of TBI. Neuropharmacology. 2019; 145:160–76. https://doi.org/10.1016/j.neuropharm.2018.06.021 PMID:29933008

105. Harding KE, Robertson NP. Traumatic brain injury: risk factors and prognostic assessment. J Neurol. 2013; 260:2691–93. https://doi.org/10.1007/s00415-013-7106-9 PMID:24052117

106. Danielyan L, Beer-Hammer S, Stolzing A, Schäfer R, Siegel G, Fabian C, Kahle P, Biedermann T, Lourhmati A, Buadze M, Novakovic A, Proksch B, Gleiter CH, et al.
Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of Alzheimer’s and Parkinson’s disease. Cell Transplant. 2014 (Suppl 1); 23:S123–39. https://doi.org/10.3727/096368914X684970 PMID: 25302802

107. Wong JC, Hazrati LN. Parkinson’s disease, parkinsonism, and traumatic brain injury. Crit Rev Clin Lab Sci. 2013; 50:103–06. https://doi.org/10.3109/10408363.2013.844678 PMID: 24156652

108. Kim C, Spencer B, Rockenstein E, Yamakado H, Mante M, Adame A, Fields JA, Masliah D, Iba M, Lee HJ, Rissman RA, Lee SJ, Masliah E. Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation. Mol Neurodegener. 2018; 13:43. https://doi.org/10.1186/s13024-018-0276-2 PMID: 30092810

109. Rocha EM, De Miranda B, Sanders LH. Alpha-synuclein: pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease. Neurobiol Dis. 2018; 109:249–57. https://doi.org/10.1016/j.nbd.2017.04.004 PMID: 28400134

110. Acosta SA, Tajiri N, de la Pena I, Bastawrous M, Sanberg PR, Kaneko Y, Borlongan CV. Alpha-synuclein as a pathological link between chronic traumatic brain injury and Parkinson’s disease. J Cell Physiol. 2015; 230:1024–32. https://doi.org/10.1002/jcp.24830 PMID: 25251017

111. Taguchi K, Watanabe Y, Tsujimura A, Tanaka M. Brain region-dependent differential expression of alpha-synuclein. J Comp Neurol. 2016; 524:1236–58. https://doi.org/10.1002/cne.23901 PMID: 26358191

112. Taguchi K, Watanabe Y, Tsujimura A, Tanaka M. Expression of α-synuclein is regulated in a neuronal cell type-dependent manner. Anat Sci Int. 2019; 94:11–22. https://doi.org/10.1007/s12565-018-0464-8 PMID: 30362073

113. Roberts RF, Wade-Martins R, Alegre-Abarrategui J. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson’s disease brain. Brain. 2015; 138:1642–57. https://doi.org/10.1093/brain/avv040 PMID: 25732184

114. Bridi JC, Hirth F. Mechanisms of α-synuclein induced synaptopathy in Parkinson’s disease. Front Neurosci. 2018; 12:80. https://doi.org/10.3389/fnins.2018.00080 PMID: 29515354

115. Sacino AN, Brooks MM, Chakrabarty P, Saha K, Khoshbouei H, Golde TE, Giasson BI. Proteolysis of α-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology. J Neurochem. 2017; 140:662–78. https://doi.org/10.1111/jnc.13743 PMID: 27424880

116. Levy Nogueira M, Hamraz M, Abolhassani M, Bigan E, Lafitte O, Steyaert JM, Dubois B, Schwartz L. Mechanical stress increases brain amyloid β, tau, and α-synuclein concentrations in wild-type mice. Alzheimers Dement. 2018; 14:444–53. https://doi.org/10.1016/j.jalz.2017.11.003 PMID: 29244999

117. Newell KL, Boyer P, Gomez-Tortosa E, Hobbs W, Hedley-Whyte ET, Vonsattel JP, Hyman BT. Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury. J Neuropathol Exp Neurol. 1999; 58:1263–68. https://doi.org/10.1097/00005072-199912000-00007 PMID: 10604751

118. Uryu K, Chen XH, Martinez D, Browne KD, Johnson VE, Graham DI, Lee VM, Trojanowski JQ, Smith DH. Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp Neurol. 2007; 208:185–92. https://doi.org/10.1016/j.expneurol.2007.06.018 PMID: 17826768

119. Sajja VS, Hubbard WB, Hall CS, Ghodousi F, Galloway MP, VandeVord PJ. Enduring deficits in memory and neuronal pathology after blast-induced traumatic brain injury. Sci Rep. 2015; 5:15075. https://doi.org/10.1038/srep15075 PMID: 26537106

120. Carlson SW, Yan H, Dixon CE. Lithium increases hippocampal SNARE protein abundance after traumatic brain injury. Exp Neurol. 2017; 289:55–63. https://doi.org/10.1016/j.expneurol.2016.12.006 PMID: 28011122

121. Pozo Devoto VM, Falzone TL. Mitochondrial dynamics in Parkinson’s disease: a role for α-synuclein? Dis Model Mech. 2017; 10:1075–87. https://doi.org/10.1242/dmm.026294 PMID: 28883016

122. Kim T, Vemuganti R. Mechanisms of Parkinson’s disease-related proteins in mediating secondary brain damage after cerebral ischemia. J Cereb Blood Flow
123. Zhao HQ, Li FF, Wang Z, Wang XM, Feng T. A comparative study of the amount of α-synuclein in ischemic stroke and Parkinson’s disease. Neurol Sci. 2016; 37:749–54. https://doi.org/10.1007/s10072-016-2485-1 PMID:26829934

124. Hu X, Rea HC, Wiktorowicz JE, Perez-Polo JR. Proteomic analysis of hypoxia/ischemia-induced alteration of cortical development and dopamine neurotransmission in neonatal rat. J Proteome Res. 2006; 5:2396–404. https://doi.org/10.1021/pr060209x PMID:16944952

125. Yoon DK, Hwang IK, Yoo KY, Lee YB, Lee JJ, Kim JH, Kang TC, Lee BH, Sohn HS, Won MH. Comparison of alpha-synuclein immunoreactivity and protein levels in ischemic hippocampal CA1 region between adult and aged gerbils and correlation with Cu,Zn-superoxide dismutase. Neurosci Res. 2006; 55:434–41. https://doi.org/10.1016/j.neures.2006.04.014 PMID:16759729

126. Unal-Cevik I, Gursoy-Ozdemir Y, Yemisci M, Lule S, Gurer G, Can A, Müller V, Kahle PJ, Dalkara T. Alpha-synuclein aggregation induced by brief ischemia negatively impacts neuronal survival in vivo: a study in [A30P]alpha-synuclein transgenic mouse. J Cereb Blood Flow Metab. 2011; 31:913–23. https://doi.org/10.1038/jcbfm.2010.170 PMID:20877387

127. Sato K, Yamashita T, Kurata T, Lukic V, Fukui Y, Hishikawa N, Deguchi K, Abe K. Telmisartan reduces progressive oxidative stress and phosphorylated α-synuclein accumulation in stroke-resistant spontaneously hypertensive rats after transient middle cerebral artery occlusion. J Stroke Cerebrovasc Dis. 2014; 23:1554–63. https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.12.051 PMID:24780412

128. Kim T, Mehta SL, Morris-Blanco KC, Chokkalla AK, Chelluboina B, Lopez M, Sullivan R, Kim HT, Cook TD, Kim JY, Kim H, Kim C, Vemuganti R. The microRNA miR-7a-5p ameliorates ischemic brain damage by repressing α-synuclein. Sci Signal. 2018; 11:eaat4285. https://doi.org/10.1126/scisignal.aat4285 PMID:30538177

129. Ahmad AS. PGD2 DP1 receptor stimulation following stroke ameliorates cerebral blood flow and outcomes. Neuroscience. 2014; 279:260–68. https://doi.org/10.1016/j.neuroscience.2014.08.050 PMID:25218962

130. Kim T, Mehta SL, Kaimal B, Lyons K, Dempsey RJ, Vemuganti R. Poststroke induction of α-synuclein mediates ischemic brain damage. J Neurosci. 2016; 36:7055–65. https://doi.org/10.1523/JNEUROSCI.1241-16.2016 PMID:27358461

131. Gui YX, Wang XY, Kang WY, Zhang YJ, Zhang Y, Zhou Y, Quinn TJ, Liu J, Chen SD. Extracellular signal-regulated kinase is involved in alpha-synuclein-induced mitochondrial dynamic disorders by regulating dynamin-like protein 1. Neurobiol Aging. 2012; 33:2841–54. https://doi.org/10.1016/j.neurobiolaging.2012.02.001 PMID:22445325

132. Winslow AR, Chen CW, Corrochano S, Acevedo-Arozena A, Gordon DE, Peden AA, Lichtenberg M, Menzies FM, Ravikumar B, Imarisio S, Brown S, O’Kane CJ, Rubinsztein DC. A-synuclein impairs macroautophagy: implications for Parkinson’s disease. J Cell Biol. 2010; 190:1023–37. https://doi.org/10.1083/jcb.201003122 PMID:20855006